Literature DB >> 21274371

Peginterferon and ribavirin treatment for hepatitis C virus infection.

Akihito Tsubota1, Kiyotaka Fujise, Yoshihisa Namiki, Norio Tada.   

Abstract

Pegylated interferon α (IFNα) in combination with ribavirin is currently recommended as a standard-of-care treatment for chronic hepatitis C virus (HCV) infection. This combination therapy has drastically improved the rate of sustained virological response, specifically in difficult-to-treat patients. Recently, individualized treatment, such as response-guided therapy, is being developed based on host-, HCV- and treatment-related factors. Furthermore, modified regimens with currently available medications, novel modified IFNα and ribavirin or combinations with specifically targeted antiviral therapy for HCV agents, are currently being investigated. The purpose of this review is to address some issues and epoch-making topics in the treatment of chronic HCV infection, and to discuss more optimal and highly individualized therapeutic strategies for HCV-infected patients.

Entities:  

Keywords:  Chronic hepatitis C virus infection; Difficult-to-treat patient; Individualized treatment; Pegylated interferon α; Response-guided therapy; Ribavirin; Specifically targeted antiviral therapy for hepatitis C virus

Mesh：

Substances：

Year:  2011        PMID： 21274371      PMCID： PMC3027008          DOI： 10.3748/wjg.v17.i4.419

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  115 in total

1.  Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C.

Authors:  Eva Martínez-Bauer; Javier Crespo; Manuel Romero-Gómez; Ricardo Moreno-Otero; Ricard Solá; Nancy Tesei; Fernando Pons; Xavier Forns; José M Sánchez-Tapias
Journal:  Hepatology       Date:  2006-01       Impact factor: 17.425

2.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

Authors:  P Bailon; A Palleroni; C A Schaffer; C L Spence; W J Fung; J E Porter; G K Ehrlich; W Pan; Z X Xu; M W Modi; A Farid; W Berthold; M Graves
Journal:  Bioconjug Chem       Date:  2001 Mar-Apr       Impact factor: 4.774

3.  Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

Authors:  José M Sánchez-Tapias; Moisés Diago; Pedro Escartín; Jaime Enríquez; Manuel Romero-Gómez; Rafael Bárcena; Javier Crespo; Raúl Andrade; Eva Martínez-Bauer; Ramón Pérez; Milagros Testillano; Ramón Planas; Ricard Solá; Manuel García-Bengoechea; Javier Garcia-Samaniego; Miguel Muñoz-Sánchez; Ricardo Moreno-Otero
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

4.  High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

Authors:  Karin Lindahl; Lars Stahle; Annette Bruchfeld; Robert Schvarcz
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

5.  Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model.

Authors:  F C Bekkering; C Stalgis; J G McHutchison; J T Brouwer; A S Perelson
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

6.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

7.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

Authors:  John G McHutchison; Michael Manns; Keyur Patel; Thierry Poynard; Karen L Lindsay; Christian Trepo; Jules Dienstag; William M Lee; Carmen Mak; Jean-Jacques Garaud; Janice K Albrecht
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

8.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.

Authors:  K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi; Y Higashi; M Shibata; T Morishima
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

9.  Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.

Authors:  David R Nelson; Vinod Rustgi; Vijayan Balan; Mark S Sulkowski; Gary L Davis; Andrew J Muir; Louis R Lambiase; Rolland C Dickson; Russell H Weisner; Michele Fiscella; Patrick W Cronin; Erik Pulkstenis; John G McHutchison; G Mani Subramanian
Journal:  Clin Gastroenterol Hepatol       Date:  2008-11-07       Impact factor: 11.382

10.  Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals.

Authors:  Chin-chung Lin; Li-Tain Yeh; Domenico Vitarella; Zhi Hong
Journal:  Antivir Chem Chemother       Date:  2003-05
View more
  20 in total

1.  Effect of discounting on estimation of benefits determined by hepatitis C treatment.

Authors:  Andrea Messori; Valeria Fadda; Dario Maratea; Sabrina Trippoli
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

2.  Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model.

Authors:  Hannah Perkins; Tansi Khodai; Houria Mechiche; Peter Colman; Frances Burden; Carl Laxton; Nigel Horscroft; Tom Corey; Deborah Rodrigues; Jaiessh Rawal; Jonathan Heyen; Mark Fidock; Mike Westby; Helen Bright
Journal:  J Clin Immunol       Date:  2012-04-05       Impact factor: 8.317

Review 3.  Host-Directed Antiviral Therapy.

Authors:  Naveen Kumar; Shalini Sharma; Ram Kumar; Bhupendra N Tripathi; Sanjay Barua; Hinh Ly; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

4.  Interleukin-28B polymorphisms are associated with an early viral response in patients receiving hepatitis C therapy.

Authors:  Rie Osaki; Takashi Nishimura; Takayuki Takeuchi; Hirotsugu Imaeda; Yoshiaki Okumura; Makoto Shioya; Tamio Nakahara; Shigeki Bamba; Shinobu Nakajo; Yoshihide Fujiyama; Akira Andoh
Journal:  Exp Ther Med       Date:  2011-04-07       Impact factor: 2.447

5.  Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?

Authors:  Raquel Francine Liermann Garcia; Simone Moreira; Ana Lucia de Araújo Ramos; Leslie Ecker Ferreira; Angelo Alves de Mattos; Cristiane Valle Tovo; Lysandro Alsina Nader; Juliene Antonio Ramos; Edson Rondinelli; Arnaldo de Jesus Dominici; Christian Evangelista Garcia; Mauro de Souza Leite Pinho; Carlos Eduardo Brandão-Mello; Cristiane Alves Villela-Nogueira; Paulo Henrique Condeixa de França
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

Review 6.  New treatments for chronic hepatitis C: an overview for paediatricians.

Authors:  Daniele Serranti; Giuseppe Indolfi; Massimo Resti
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

7.  Modulation of PI3K-LXRα-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin.

Authors:  Sandra Pisonero-Vaquero; María V García-Mediavilla; Francisco Jorquera; Pedro L Majano; Marta Benet; Ramiro Jover; Javier González-Gallego; Sonia Sánchez-Campos
Journal:  Lab Invest       Date:  2014-02-03       Impact factor: 5.662

8.  A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon.

Authors:  Marianne Berger Rentsch; Gert Zimmer
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

9.  Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes.

Authors:  Jie Guan; Bo Wen; Yao Deng; Ke Zhang; Hong Chen; Xiaobing Wu; Li Ruan; Wenjie Tan
Journal:  Virol J       Date:  2011-11-04       Impact factor: 4.099

Review 10.  Future research and collaboration: the "SINERGIE" project on HCV (South Italian Network for Rational Guidelines and International Epidemiology).

Authors:  C Torti; M Zazzi; L Abenavoli; F Trapasso; F Cesario; D Corigliano; L Cosco; C Costa; R L Curia; M De Rosa; G Foti; C Giraldi; R Leone; M C Liberto; D Lucchino; N Marascio; R Masciari; G Matera; V Pisani; N Serrao; L Surace; E Zicca; F Castelli; M Ciccozzi; M Puoti; A Focà
Journal:  BMC Infect Dis       Date:  2012-11-12       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.